Assertio Holdings Inc
NASDAQ:ASRT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
0.5341
0.9747
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Assertio Holdings Inc
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. The company is headquartered in Lake Forest, Illinois and currently employs 19 full-time employees. The firm's primary marketed products are INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, INDOCIN (indomethacin) Oral Suspension, CAMBIA (diclofenac potassium for oral solution), Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray and Zipsor (diclofenac potassium) Liquid filled capsules. The firm has other commercially available products, which include OXAYDO (oxycodone HCI, USP) tablets for oral use only. Assertio and Zyla are the registered trademarks of the Company. INDOCIN products are used for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease, moderate to severe ankylosing spondylitis, moderate to severe osteoarthritis, acute painful shoulder (bursitis and/or tendinitis) and acute gouty arthritis.
Rolvedon Sales Surge: Assertio reported Rolvedon net product sales of $38.6 million in Q3 2025, up sharply from $15 million a year ago due to a two-quarter sales pull-forward.
Strong Profit Growth: Adjusted EBITDA rose to $20.9 million from $4.4 million last year, primarily driven by the Rolvedon pull-forward.
Guidance Narrowed: Full-year 2025 product sales guidance tightened to $110–112 million and adjusted EBITDA to $14–16 million, reflecting greater visibility after the Rolvedon pull-forward.
Temporary Cash Flow Dip: The Rolvedon sales shift will cause a temporary drop in operating cash flow over the next two quarters, with sales of newly labeled Rolvedon expected to resume in Q2 2026.
Sympazan Grows Modestly: Sympazan sales edged up to $2.8 million from $2.6 million, supported by higher volume.
Indocin Declines: Indocin sales fell to $4.8 million from $5.7 million, as expected from rising generic competition.
Gross Margin Dips: Gross margin decreased to 72% from 74% last year due to the higher mix of Rolvedon sales.
